Topiramate therapy for paroxysmal kinesigenic choreoathetosis

✍ Scribed by Yuan-Gui Huang; Yun-Chun Chen; Fang Du; Rui Li; Ge-Lin Xu; Wen Jiang; Jing Huang

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 53 KB
• Volume: 20
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.20283

✦ Synopsis

Abstract

We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow‐up period ranged from 8 months to 2 years. All of the patients became attack‐free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect. © 2004 Movement Disorder Society